# Alumis Inc.: overview

ALMS · Nasdaq · CIK 1847367 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alms.md) · [Financials](/companies/alms/financials.md) · [Filings](/companies/alms/filings.md) · [Insiders](/companies/alms/insiders.md)

Latest reported revenue: [$1.7m](/filings/0001847367-26-000018.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001847367-26-000018).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [17.4](/filings/0001847367-26-000010.md) | [2.7](/filings/0001847367-26-000018.md) | [2.1](/filings/0001847367-25-000050.md) | [1.9 d](/filings/0001847367-26-000006.md) | [1.7](/filings/0001847367-26-000010.md) | [1.7](/filings/0001847367-26-000018.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(583.9%)](/filings/0001847367-26-000010.md) | [(5271.5%)](/filings/0001847367-26-000018.md) | [(5580.4%)](/filings/0001847367-25-000050.md) | [(4999.7%) d](/filings/0001847367-26-000006.md) | [(5652.4%)](/filings/0001847367-26-000010.md) | [(8956.4%)](/filings/0001847367-26-000018.md) |
| Net margin | % | not reported | not reported | [(569.1%)](/filings/0001847367-26-000018.md) | [2225.1%](/filings/0001847367-26-000018.md) | [(5360.7%)](/filings/0001847367-25-000050.md) | [(4817.6%) d](/filings/0001847367-26-000006.md) | [(5344.8%)](/filings/0001847367-26-000018.md) | [(8557.2%)](/filings/0001847367-26-000018.md) |
| Diluted EPS | $ per share | [(1.73)](/filings/0001847367-25-000050.md) | not reported | [(1.82)](/filings/0001847367-26-000010.md) | [0.77](/filings/0001847367-26-000018.md) | [(1.06)](/filings/0001847367-25-000050.md) | not reported | [(0.74)](/filings/0001847367-26-000010.md) | [(1.11)](/filings/0001847367-26-000018.md) |
| Free cash flow | $m | [(84.5) d](/filings/0001847367-25-000050.md) | [(75.1) d](/filings/0001847367-26-000006.md) | [(80.4)](/filings/0001847367-26-000010.md) | [(107) d](/filings/0001847367-26-000018.md) | [(111) d](/filings/0001847367-25-000050.md) | [(71.9) d](/filings/0001847367-26-000006.md) | [(87.2)](/filings/0001847367-26-000010.md) | [(81.7) d](/filings/0001847367-26-000018.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [24.1](/filings/0001847367-26-000006.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(1886.9%)](/filings/0001847367-26-000006.md) |
| Net margin | % | not reported | not reported | [(1011.7%)](/filings/0001847367-26-000006.md) |
| Diluted EPS | $ per share | [(72.08)](/filings/0001847367-25-000012.md) | [(10.38)](/filings/0001847367-26-000006.md) | [(2.86)](/filings/0001847367-26-000006.md) |
| Free cash flow | $m | [(134)](/filings/0001847367-25-000012.md) | [(257)](/filings/0001847367-26-000006.md) | [(370)](/filings/0001847367-26-000006.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alms/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [AyurMaya Capital Management Company, LP](/funds/1975990.md) | 2026-06-30 | $426.0m | 15,139,707 |  | Not compared |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $231.3m | 8,218,151 |  | Added +1,047,283 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $190.5m | 6,769,170 |  | Added +5,795,388 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $178.6m | 6,348,558 |  | Reduced −424,037 |
| [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $178.6m | 6,345,219 |  | Unchanged |
| [Foresite Capital Management V, LLC](/funds/1792206.md) | 2026-06-30 | $165.9m | 5,896,995 |  | Unchanged |
| [venBio Partners LLC](/funds/1776382.md) | 2026-06-30 | $127.4m | 4,528,408 |  | Unchanged |
| [Foresite Capital Management VI LLC](/funds/2013341.md) | 2026-06-30 | $119.5m | 4,247,670 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $118.6m | 4,215,703 |  | Added +183,437 |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $99.6m | 3,540,998 |  | Unchanged |

## Recent filings

[All 240 filings](/companies/alms/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-01 | 08:30 ET | [8-K](/filings/0001104659-26-104145.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-104145 |
| 2026-08-13 | 16:19 ET | [10-Q](/filings/0001847367-26-000018.md) | Quarterly report, period 2026-06-30 | 0001847367-26-000018 |
| 2026-08-13 | 16:07 ET | [8-K](/filings/0001847367-26-000016.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001847367-26-000016 |
| 2026-08-10 | 16:06 ET | [8-K](/filings/0001104659-26-093353.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-093353 |
| 2026-07-02 | 17:01 ET | [SCHEDULE 13D/A](/filings/0000950142-26-001978.md) | Ownership report, active investor, amended | 0000950142-26-001978 |
| 2026-07-02 | 16:30 ET | [8-K](/filings/0001104659-26-080361.md) | 5.07 Shareholder vote results | 0001104659-26-080361 |
| 2026-06-29 | 08:01 ET | [8-K](/filings/0001104659-26-078507.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-078507 |
| 2026-05-18 | 16:27 ET | [DEF 14A](/filings/0001104659-26-063223.md) | Proxy statement, period 2026-06-30 | 0001104659-26-063223 |
| 2026-05-14 | 16:16 ET | [10-Q](/filings/0001847367-26-000010.md) | Quarterly report, period 2026-03-31 | 0001847367-26-000010 |
| 2026-05-14 | 16:09 ET | [8-K](/filings/0001847367-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001847367-26-000009 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001847367-26-000006.md), filed Mar 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ca3541bb-b8d2-4a89-9742-d6958051b846)

## About the filer

- CIK: 1847367
- Tickers: ALMS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.